Works matching AU Vugts, Danielle J.

Results: 73
    1

    Preclinical Evaluation of <sup>89</sup>Zr-Desferrioxamine-Bexmarilimab, a Humanized Antibody Against Common Lymphatic Endothelial and Vascular Endothelial Receptor-1, in a Rabbit Model of Renal Fibrosis.

    Published in:
    Journal of Nuclear Medicine, 2023, v. 64, n. 4, p. 555, doi. 10.2967/jnumed.122.264725
    By:
    • Moisio, Olli;
    • Virta, Jenni;
    • Yatkin, Emrah;
    • Liljenbäck, Heidi;
    • Palani, Senthil;
    • Viitanen, Riikka;
    • Miner, Maxwell W. G.;
    • Oikonen, Vesa;
    • Tolvanen, Tuula;
    • Vugts, Danielle J.;
    • Taimen, Pekka;
    • Xiang-Guo Li;
    • Hollmén, Maija;
    • Jalkanen, Sirpa;
    • Roivainen, Anne
    Publication type:
    Article
    2

    <sup>89</sup>Zr-Labeled High-Density Lipoprotein Nanoparticle PET Imaging Reveals Tumor Uptake in Patients with Esophageal Cancer.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 12, p. 1880, doi. 10.2967/jnumed.121.263330
    By:
    • Zheng, Kang H.;
    • Kroon, Jeffrey;
    • Schoormans, Jasper;
    • Gurney-Champion, Oliver;
    • Meijer, Sybren L.;
    • Gisbertz, Suzanne S.;
    • Hulshof, Maarten C. C. M.;
    • Vugts, Danielle J.;
    • van Dongen, Guus A. M. S.;
    • Coolen, Bram F.;
    • Verberne, Hein J.;
    • Nederveen, Aart J.;
    • Stroes, Erik S. G.;
    • van Laarhoven, Hanneke W. M.
    Publication type:
    Article
    3

    <sup>89</sup>Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.263330
    By:
    • Zheng, Kang H.;
    • Kroon, Jeffrey;
    • Schoormans, Jasper;
    • Gurney-Champion, Oliver;
    • Meijer, Sybren L.;
    • Gisbertz, Suzanne S.;
    • Hulshof, Maarten C. C. M.;
    • Vugts, Danielle J.;
    • van Dongen, Guus A. M. S.;
    • Coolen, Bram F.;
    • Verberne, Hein J.;
    • Nederveen, Aart J.;
    • Stroes, Erik S. G.;
    • van Laarhoven, Hanneke W. M.
    Publication type:
    Article
    4

    <sup>89</sup>Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.263330
    By:
    • Kang H. Zheng;
    • Kroon, Jeffrey;
    • Schoormans, Jasper;
    • Gurney-Champion, Oliver;
    • Meijer, Sybren L.;
    • Gisbertz, Suzanne S.;
    • Hulshof, Maarten C. C. M.;
    • Vugts, Danielle J.;
    • van Dongen, Guus A. M. S.;
    • Coolen, Bram F.;
    • Verberne, Hein J.;
    • Nederveen, Aart J.;
    • Stroes, Erik S. G.;
    • van Laarhoven, Hanneke W. M.
    Publication type:
    Article
    5

    <sup>89</sup>Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.

    Published in:
    Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.263330
    By:
    • Zheng, Kang H.;
    • Kroon, Jeffrey;
    • Schoormans, Jasper;
    • Gurney-Champion, Oliver;
    • Meijer, Sybren L.;
    • Gisbertz, Suzanne S.;
    • Hulshof, Maarten C. C. M.;
    • Vugts, Danielle J.;
    • van Dongen, Guus A. M. S.;
    • Coolen, Bram F.;
    • Verberne, Hein J.;
    • Nederveen, Aart J.;
    • Stroes, Erik S. G.;
    • van Laarhoven, Hanneke W. M.
    Publication type:
    Article
    6
    7
    8
    9

    PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.

    Published in:
    Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262473
    By:
    • Smit, Jasper;
    • Borm, Frank J.;
    • Niemeijer, Anna-Larissa N.;
    • Huisman, Marc C.;
    • Hoekstra, Otto S.;
    • Boellaard, Ronald;
    • Oprea – Lager, Daniela E.;
    • Vugts, Danielle J.;
    • van Dongen, Guus A. M. S.;
    • de Wit- van der Veen, Berlinda J.;
    • Thunnissen, Erik;
    • Smit, Egbert F.;
    • de Langen, Adrianus J.
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17
    18

    ImmunoPET imaging to assess target engagement: Experience from 89Zr‐anti‐HER3 mAb (GSK2849330) in patients with solid tumors.

    Published in:
    Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.118.214726
    By:
    • Willemien Menke‐van der Houven van Oordt, C.;
    • McGeoch, Adam;
    • Bergstrom, Mats;
    • McSherry, Iain;
    • Smith, Deborah A.;
    • Cleveland, Matthew;
    • Al‐Azzam, Wasfi;
    • Liangfu Chen;
    • Verheul, Henk;
    • Hoekstra, Otto S.;
    • Vugts, Danielle J.;
    • Freedman, Immanuel;
    • Huisman, Marc;
    • Matheny, Chris;
    • Guus van Dongen;
    • Sean Zhang
    Publication type:
    Article
    19

    Immuno-PET Imaging to Assess Target Engagement: Experience from <sup>89</sup>Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors.

    Published in:
    Journal of Nuclear Medicine, 2019, v. 60, n. 7, p. 902, doi. 10.2967/jnumed.118.214726
    By:
    • Menke-van der Houven van Oordt, C. Willemien;
    • McGeoch, Adam;
    • Bergstrom, Mats;
    • McSherry, Iain;
    • Smith, Deborah A.;
    • Cleveland, Matthew;
    • Al-Azzam, Wasfi;
    • Liangfu Chen;
    • Verheul, Henk;
    • Hoekstra, Otto S.;
    • Vugts, Danielle J.;
    • Freedman, Immanuel;
    • Huisman, Marc;
    • Matheny, Chris;
    • van Dongen, Guus;
    • Sean Zhang
    Publication type:
    Article
    20
    21
    22

    Multicenter Harmonization of <sup>89</sup>Zr PET/CT Performance.

    Published in:
    Journal of Nuclear Medicine, 2014, v. 55, n. 2, p. 264, doi. 10.2967/jnumed.113.130112
    By:
    • Makris, Nikolaos E.;
    • Boellaard, Ronald;
    • Visser, Eric E.;
    • de Jong, Johan R.;
    • Vanderlinden, Bruno;
    • Wierts, Roel;
    • van der Veen, Berlinda J.;
    • Greuter, Henri J. N. M.;
    • Vugts, Danielle J.;
    • van Dongen, Guus A. M. S.;
    • Lammertsma, Adriaan A.;
    • Huisman, Marc C.
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32

    <sup>11</sup>C-labeled and <sup>18</sup>F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain <sup>11</sup>C-labeled and <sup>18</sup>F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain.

    Published in:
    Journal of Labelled Compounds & Radiopharmaceuticals, 2013, v. 56, n. 3/4, p. 120, doi. 10.1002/jlcr.3038
    By:
    • Funke, Uta;
    • Vugts, Danielle J.;
    • Janssen, Bieneke;
    • Spaans, Arnold;
    • Kruijer, Perry S.;
    • Lammertsma, Adriaan A.;
    • Perk, Lars R.;
    • Windhorst, Albert D.
    Publication type:
    Article
    33
    34

    <sup>89</sup>Zr-immuno-PET using the anti-LAG-3 tracer [<sup>89</sup>Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 7, p. 2068, doi. 10.1007/s00259-023-06164-w
    By:
    • Miedema, Iris H.C.;
    • Huisman, Marc C.;
    • Zwezerijnen, Gerben J.C.;
    • Grempler, Rolf;
    • Pitarch, Alejandro Perez;
    • Thiele, Andrea;
    • Hesse, Raphael;
    • Elgadi, Mabrouk;
    • Peltzer, Alexander;
    • Vugts, Danielle J.;
    • van Dongen, Guus A.M.S.;
    • de Gruijl, Tanja D.;
    • Menke-van der Houven van Oordt, C. Willemien;
    • Bahce, Idris
    Publication type:
    Article
    35

    Validation of simplified uptake measures against dynamic Patlak K<sub>i</sub> for quantification of lesional <sup>89</sup>Zr-Immuno-PET antibody uptake.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 7, p. 1897, doi. 10.1007/s00259-023-06151-1
    By:
    • Wijngaarden, Jessica E.;
    • Huisman, Marc C.;
    • Jauw, Yvonne W. S.;
    • van Dongen, Guus A. M. S.;
    • Greuter, Henri N. J. M.;
    • Schuit, Robert C.;
    • Cleveland, Matthew;
    • Gootjes, Elske C.;
    • Vugts, Daniëlle J.;
    • Menke-van der Houven van Oordt, C. Willemien;
    • Boellaard, Ronald
    Publication type:
    Article
    36

    In memoriam: Marion Hendriks-de Jong.

    Published in:
    2021
    By:
    • Krenning, Eric P.;
    • Krestin, Gabriel P.;
    • Bernsen, Monique R.;
    • Dalm, Simone U.;
    • Boerman, Otto C.;
    • Elsinga, Philip H.;
    • Glaudemans, Andor W. J. M.;
    • Vugts, Daniëlle J.;
    • Kunikowska, Jolanta;
    • Erba, Paola A.;
    • Evangelista, Laura;
    • Nock, Berthold A.;
    • Maina, Theodosia
    Publication type:
    Editorial
    37

    Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 3, p. 694, doi. 10.1007/s00259-020-05002-7
    By:
    • Chomet, Marion;
    • Schreurs, Maxime;
    • Bolijn, Maria J.;
    • Verlaan, Mariska;
    • Beaino, Wissam;
    • Brown, Kari;
    • Poot, Alex J.;
    • Windhorst, Albert D.;
    • Gill, Herman;
    • Marik, Jan;
    • Williams, Simon;
    • Cowell, Joseph;
    • Gasser, Gilles;
    • Mindt, Thomas L.;
    • van Dongen, Guus A. M. S;
    • Vugts, Danielle J.
    Publication type:
    Article
    38

    The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study.

    Published in:
    European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 2, p. 379, doi. 10.1007/s00259-019-04550-x
    By:
    • Hagens, Marloes H. J.;
    • Golla, Sandeep S. V.;
    • Janssen, Bieneke;
    • Vugts, Danielle J.;
    • Beaino, Wissam;
    • Windhorst, Albert D.;
    • O'Brien-Brown, James;
    • Kassiou, Michael;
    • Schuit, Robert C.;
    • Schwarte, Lothar A.;
    • de Vries, Helga E.;
    • Killestein, Joep;
    • Barkhof, Frederik;
    • van Berckel, Bart N. M.;
    • Lammertsma, Adriaan A.
    Publication type:
    Article
    39

    Investigation of the Impact of the H310A FcRn Region Mutation on <sup>89</sup>Zr-Immuno-PET Brain Imaging with a BBB-Shuttle Anti‑Amyloid Beta Antibody.

    Published in:
    Molecular Imaging & Biology, 2024, v. 26, n. 5, p. 823, doi. 10.1007/s11307-024-01931-z
    By:
    • Wuensche, Thomas E.;
    • Stergiou, Natascha;
    • Mes, Iris;
    • Verlaan, Mariska;
    • Kooijman, Esther J. M.;
    • Windhorst, Albert D.;
    • Jensen, Allan;
    • Asuni, Ayodeji A.;
    • Bang-Andersen, Benny;
    • van Dongen, Guus A. M. S.;
    • Vugts, Danielle J.;
    • Beaino, Wissam
    Publication type:
    Article
    40
    41
    42

    Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial).

    Published in:
    NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-023-00610-6
    By:
    • Mileva, Magdalena;
    • de Vries, Elisabeth G. E.;
    • Guiot, Thomas;
    • Wimana, Zéna;
    • Deleu, Anne-Leen;
    • Schröder, Carolien P.;
    • Lefebvre, Yolene;
    • Paesmans, Marianne;
    • Stroobants, Sigrid;
    • Huizing, Manon;
    • Aftimos, Philippe;
    • Tol, Jolien;
    • Van der Graaf, Winette T. A.;
    • Oyen, Wim J. G.;
    • Vugts, Danielle J.;
    • Menke-van der Houven van Oordt, C. Willemien;
    • Brouwers, Adrienne H.;
    • Piccart-Gebhart, Martine;
    • Flamen, Patrick;
    • Gebhart, Géraldine
    Publication type:
    Article
    43
    44

    Synthesis and preclinical evaluation of [<sup>11</sup>C]EAI045 as a PET tracer for imaging tumors expressing mutated epidermal growth factor receptor.

    Published in:
    EJNMMI Research, 2024, v. 14, p. 1, doi. 10.1186/s13550-024-01078-6
    By:
    • Högnäsbacka, Antonia A.;
    • Poot, Alex J.;
    • Plisson, Christophe;
    • Bergare, Jonas;
    • Bonsall, David R.;
    • McCluskey, Stuart P.;
    • Wells, Lisa A.;
    • Kooijman, Esther;
    • Schuit, Robert C.;
    • Verlaan, Mariska;
    • Beaino, Wissam;
    • van Dongen, Guus A. M. S.;
    • Vugts, Danielle J.;
    • Elmore, Charles S.;
    • Passchier, Jan;
    • Windhorst, Albert D.
    Publication type:
    Article
    45

    Non-specific irreversible <sup>89</sup>Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using <sup>89</sup>Zr-immuno-PET.

    Published in:
    EJNMMI Research, 2024, v. 14, p. 1, doi. 10.1186/s13550-024-01079-5
    By:
    • Wijngaarden, Jessica E.;
    • Jauw, Yvonne W. S.;
    • Zwezerijnen, Gerben J. C.;
    • de Wit-van der Veen, Berlinda J.;
    • Vugts, Daniëlle J.;
    • Zijlstra, Josée M.;
    • van Dongen, Guus A. M. S.;
    • Boellaard, Ronald;
    • Menke-van der Houven van Oordt, C. Willemien;
    • Huisman, Marc C.
    Publication type:
    Article
    46

    Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

    Published in:
    OncoImmunology, 2017, v. 6, n. 3, p. N.PAG, doi. 10.1080/2162402X.2016.1277306
    By:
    • Klein, Christian;
    • Waldhauer, Inja;
    • Nicolini, Valeria G.;
    • Freimoser-Grundschober, Anne;
    • Nayak, Tapan;
    • Vugts, Danielle J.;
    • Dunn, Claire;
    • Bolijn, Marije;
    • Benz, Jörg;
    • Stihle, Martine;
    • Lang, Sabine;
    • Roemmele, Michaele;
    • Hofer, Thomas;
    • van Puijenbroek, Erwin;
    • Wittig, David;
    • Moser, Samuel;
    • Ast, Oliver;
    • Brünker, Peter;
    • Gorr, Ingo H.;
    • Neumann, Sebastian
    Publication type:
    Article
    47

    Non invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.

    Published in:
    PLoS ONE, 2017, v. 12, n. 4, p. 1, doi. 10.1371/journal.pone.0176075
    By:
    • Alsaid, Hasan;
    • Skedzielewski, Tinamarie;
    • Rambo, Mary V.;
    • Hunsinger, Kristen;
    • Hoang, Bao;
    • Fieles, William;
    • Long, Edward R.;
    • Tunstead, James;
    • Vugts, Danielle J.;
    • Cleveland, Matthew;
    • Clarke, Neil;
    • Matheny, Christopher;
    • Jucker, Beat M.
    Publication type:
    Article
    48
    49

    Whole-Body HER2 Heterogeneity Identified on HER2 PET in HER2-Negative, -Low, and -Positive Metastatic Breast Cancer.

    Published in:
    Journal of Nuclear Medicine, 2024, v. 65, n. 10, p. 1540, doi. 10.2967/jnumed.124.267636
    By:
    • Eisses, Bertha;
    • van Geel, Jasper J.L.;
    • Brouwers, Adrienne H.;
    • Bensch, Frederike;
    • Elias, Sjoerd G.;
    • Kuip, Evelien J.M.;
    • Jager, Agnes;
    • van der Vegt, Bert;
    • Lub-de Hooge, Marjolijn N.;
    • Emmering, Jasper;
    • Arens, Anne I.J.;
    • Zwezerijnen, Gerben J.C.;
    • Vugts, Daniëlle J.;
    • Menke-van der Houven van Oordt, C. Willemien;
    • de Vries, Elisabeth G.E.;
    • Schröder, Carolina P.;
    • Bensch, F.;
    • van Es, S.;
    • van Essen-Eisses, B.;
    • Boers, J.
    Publication type:
    Article
    50